132 related articles for article (PubMed ID: 38902646)
1. Paradoxical effect of dopamine-agonists on IGF-1 in patients with prolactinoma: the role of weight.
Caprio S; Pilli T; Cantara S; Sestini F; Fioravanti C; Ciuoli C; Dalmiglio C; Corbo A; Castagna MG
BMC Endocr Disord; 2024 Jun; 24(1):94. PubMed ID: 38902646
[TBL] [Abstract][Full Text] [Related]
2. IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas.
Akirov A; Greenman Y; Glaser B; S'chigol I; Mansiterski Y; Eizenberg Y; Shraga-Slutzky I; Shimon I
Pituitary; 2018 Aug; 21(4):406-413. PubMed ID: 29728863
[TBL] [Abstract][Full Text] [Related]
3. Long-term IGF-1 monitoring in prolactinoma patients treated with cabergoline might not be indicated.
Andereggen L; Frey J; Christ E
Endocrine; 2021 Apr; 72(1):216-222. PubMed ID: 33275185
[TBL] [Abstract][Full Text] [Related]
4. Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment.
Pirchio R; Auriemma RS; Solari D; Arnesi M; Pivonello C; Negri M; de Angelis C; Cavallo LM; Cappabianca P; Colao A; Pivonello R
Front Endocrinol (Lausanne); 2021; 12():769744. PubMed ID: 34917030
[TBL] [Abstract][Full Text] [Related]
5. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
6. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Hamilton DK; Vance ML; Boulos PT; Laws ER
Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
[TBL] [Abstract][Full Text] [Related]
7. Predictors of dopamine agonist resistance in prolactinoma patients.
Vermeulen E; D'Haens J; Stadnik T; Unuane D; Barbe K; Van Velthoven V; Gläsker S
BMC Endocr Disord; 2020 May; 20(1):68. PubMed ID: 32429916
[TBL] [Abstract][Full Text] [Related]
8. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
9. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.
Ciresi A; Amato MC; Guarnotta V; Lo Castro F; Giordano C
Clin Endocrinol (Oxf); 2013 Dec; 79(6):845-52. PubMed ID: 23506485
[TBL] [Abstract][Full Text] [Related]
10. MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment.
Eroukhmanoff J; Tejedor I; Potorac I; Cuny T; Bonneville JF; Dufour H; Weryha G; Beckers A; Touraine P; Brue T; Castinetti F
Eur J Endocrinol; 2017 Mar; 176(3):323-328. PubMed ID: 28073906
[TBL] [Abstract][Full Text] [Related]
11. Metabolic effects of dopamine-agonists treatment among patients with prolactinomas.
Kabootari M; Shirmohammadli H; Golgiri F; Mosalamiaghili S; Khajavi A; Akbari H
Endocrine; 2023 Mar; 79(3):537-544. PubMed ID: 36352337
[TBL] [Abstract][Full Text] [Related]
12. Mean platelet volume in patients with prolactinoma.
Tam AA; Kaya C; Başer H; Ersoy R; Çakır B
Arch Endocrinol Metab; 2016 Aug; 60(4):319-22. PubMed ID: 26886093
[TBL] [Abstract][Full Text] [Related]
13. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
14. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
[TBL] [Abstract][Full Text] [Related]
15. Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas.
George LD; Nicolau N; Scanlon MF; Davies JS
Clin Endocrinol (Oxf); 2000 Nov; 53(5):595-9. PubMed ID: 11106920
[TBL] [Abstract][Full Text] [Related]
16. Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal.
Teixeira M; Souteiro P; Carvalho D
Pituitary; 2017 Aug; 20(4):464-470. PubMed ID: 28523537
[TBL] [Abstract][Full Text] [Related]
17. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
18. Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal.
Santharam S; Fountas A; Tampourlou M; Arlt W; Ayuk J; Gittoes N; Toogood A; Karavitaki N
Clin Endocrinol (Oxf); 2018 Sep; 89(3):346-353. PubMed ID: 29894000
[TBL] [Abstract][Full Text] [Related]
19. Prolactinomas: evolution after menopause.
Mallea-Gil MS; Manavela M; Alfieri A; Ballarino MC; Chervin A; Danilowicz K; Diez S; Fainstein Day P; García-Basavilbaso N; Glerean M; Guitelman M; Katz D; Loto MG; Martinez M; Miragaya K; Moncet D; Rogozinski AS; Servidio M; Stalldecker G; Vitale M; Boero L
Arch Endocrinol Metab; 2016 Feb; 60(1):42-6. PubMed ID: 26909481
[TBL] [Abstract][Full Text] [Related]
20. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy.
Berinder K; Nyström T; Höybye C; Hall K; Hulting AL
Pituitary; 2011 Sep; 14(3):199-207. PubMed ID: 21128120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
